* All times shown in EST
8:00 am Morning Speed Networking
Synopsis
Grab a coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!8:50 am Chair’s Opening Remarks
EXOSOMES AS COVID-19 TREATMENT AGENTS
9:00 am Development of Therapeutic Exosomes
Synopsis
- Exosomes as a vaccine for COVID-19
- CAP-1002 for the treatment of COVID-19
9:30 am Breakout Group Discussions: Exosomes as Viral Treatment Agents
Join a dedicated discussion group for this deep-dive session into your chosen topic. Discuss, share and debate in small breakout groups to find actionable takeaways and explore the innovative applications of exosomes as vaccine vectors. Progress to speed networking to continue making new connections!
How are we engineering exosomes for viral applications? What lessons have we learned to improve from the COVID-19 response?
Lessons learned from the COVID-19 response: What hurdles are stopping common exosome use in vaccine delivery & how can we overcome these?
The impact on business: How have the disruptive months of 2020 influenced the therapeutic landscape from a business perspective, & how can each stakeholder work together more effectively to accelerate therapeutic development?
UNCOVERING CELL BIOLOGY TO IMPROVE EXOSOMES AS DRUG DELIVERY VEHICLES
Moderador: Xandra Breakefield , Professor, Neurology & Geneticist, Neurology & Radiology,
Harvard Medical School & Massachusetts General Hospital
Moderador: Xandra Breakefield
10:30 am Therapeutic Implications of Complex Signaling Networks on Exosomes that Orchestrates the Development of Neuronal Circuits
Synopsis
- Uncovering codes for content packaging into exosomes
- Signaling networks on exosomes are continuously evolving during the development of neuronal circuits
- Considering the therapeutic implications of the codes of packaging and evolution of exosome content
11:00 am Mesenchymal Stem Cell-Derived Extracellular Vesicles: Potential Modulators of the Immune System in Many Diseases
Synopsis
- According to controversial reports in the MSC field, especially since a phase III clinical trial failed to show clinical efficacy in MSC treated GvHD patients, we consider that MSC-EV preparations do not warrant therapeutic successes in general
- At the experimental level we confirmed EVs prepared from MSCs of different donors can significantly vary in their immunomodulatory
capabilities in vitro and in vivo and only a proportion shows the expected activities - Addressing several challenges to various aspects of scaling the MSC-EV production process
11:30 am Fundamental Aspects & Therapeutic Applications of Live Imaging of Single EV In Vivo
Synopsis
- Zebrafish embryo is a unique model organism to live-track endogenous and injected EV at vesicle scale through the whole organism up to their target cells
- This organism provides a new pre-clinical model to test in vivo EVs that are harnessed as drug vehicles
12:00 pm Virtual Speed Networking
Synopsis
Grab a coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!
12:30 pm Purification of EVs From Infected Cells for Diagnostic & Therapeutic Purposes
Synopsis
- Learn about the purifications of EVs away from viruses
- Use of large scale EV purification and characterization from drug treated cells
- Uncover function of EVs on both infected and uninfected cells
12:45 pm Use of Stem Cell EVs as a Holistic Approach to CNS Repair
Synopsis
- Examine large scale isolation of stem cell (e.g. MSC, iPSC) EVs
- Learn about the biochemical and physical characterization of stem cell EVs
- Explore the in vitro functional analysis of stem cell EVs for CNS repair
1:00 pm MSC-NTF Exosomes as a Potential Treatment for Covid-19 ARDS & Related Disorders
Synopsis
- Review of MSC and MSC-NTF exosome in vitro characteristics
- Potential application MSC-NTF exosomes in COVID-ARDS and other related disorders
- MSC-NTF vs. MSC exosomes preclinical data in ARDS model
1:30 pm Applying Placental MSC-Derived Exosomes to Treat Neurological Disorders & Congenital Diseases
Synopsis
- Exploring the neuroprotective biology of exosomes and their applications for spina bifida, a structural birth defect
- Understanding extracellular interactions of exosomes to improve targeted delivery and therapies
- Improving yield and engineering exosomes for regenerative medicine applications
2:00 pm Virtual Speed Networking
Synopsis
Grab a coffee from the comfort of your own kitchen and jump into this 1:1 networking session to make new connections, exchange virtual business cards and maybe even see a friendly face or two!
STREAMLINING COMMERCIALIZATION, PARTNERSHIPS & REGULATORY SUBMISSIONS
2:30 pm Commercializing Novel Therapeutics with Strategic Collaborations
Synopsis
- Sourcing the right partner to meet your business goals
- Discussing IP to protect therapeutic candidates
- Overcoming contractual challenges for mutually beneficial partnerships and long-standing collaborations
3:00 pm Pre-Clinical Development of Exosome-Based Therapeutics: Challenges, Barriers & Opportunities
Synopsis
- Early establishment of scalable and controlled processes for the manufacturing of exosomes for clinical application
- Challenges posed by the regulatory framework
- Funding and strategic partnerships as drivers for the transition to clinical development
3:30 pm Panel Discussion: Commercialization, Partnerships & Regulation
Synopsis
- What lessons have the leading companies in the field learned from their collaborations and submissions to date?
- How can technology choice affect your commercial result?
- Delving into recent regulatory conversations to inform trial design and, ultimately, maximize market access later in development
